Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. HPV-prevalence in elderly women in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Patterns of treatment failure in patients undergoing adjuvant or definitive radiotherapy for vulvar cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • I B Vergote
  • B Lund
  • U Peen
  • Z Umajuridze
  • M Mau-Sorensen
  • A Kranich
  • E Van Nieuwenhuysen
  • C Haslund
  • T Nottrup
  • S N Han
  • N Concin
  • T J Unger
  • Y Chai
  • N Au
  • T Rashal
  • A Joshi
  • M Crochiere
  • Y Landesman
  • J Shah
  • S Shacham
  • M Kauffman
  • M R Mirza
Vis graf over relationer

BACKGROUND: Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent gynecological malignancies.

METHODS: In this phase 2 trial, patients received selinexor (35 or 50 mg/m2 twice-weekly [BIW] or 50 mg/m2 once-weekly [QW]) in 4-week cycles. Primary endpoint was disease control rate (DCR) including complete response (CR), partial response (PR) or stable disease (SD) ≥12 weeks. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety.

RESULTS: 114 patients with ovarian (N = 66), endometrial (N = 23) or cervical (N = 25) cancer were enrolled. Median number of prior regimens for ovarian, endometrial and cervical cancer was 6 (1-11), 2 (1-5), and 3 (1-6) respectively. DCR was 30% (ovarian 30%; endometrial 35%; cervical 24%), which included confirmed PRs in 8%, 9%, and 4% of patients with ovarian, endometrial, and cervical cancer respectively. Median PFS and OS for patients with ovarian, endometrial and cervical cancer were 2.6, 2.8 and 1.4 months, and 7.3, 7.0, and 5.0 months, respectively. Common Grade 3/4 adverse events (AEs) were thrombocytopenia (17%), fatigue (14%), anemia (10%), nausea (9%) and hyponatremia (9%). Patients with ovarian cancer receiving 50 mg/m2 QW had fewer high-grade AEs with similar efficacy as BIW treatment.

CONCLUSIONS: Selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. Side effects were a function of dose level and treatment frequency, similar to previous reports, reversible and mitigated with supportive care.

OriginalsprogEngelsk
TidsskriftGynecologic Oncology
Vol/bind156
Udgave nummer2
Sider (fra-til)308-314
Antal sider7
ISSN0090-8258
DOI
StatusUdgivet - feb. 2020

Bibliografisk note

Copyright © 2019 Elsevier Inc. All rights reserved.

ID: 58960805